SEC Form 4 · accession 0001829126-26-006450
Zeo ScientifiX, Inc. · ZEOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Craig Shapiro
Officer — Chief Medical Officer · Director
Period of report
Jun 10, 2026
Accepted (ET)
Jun 12, 2026 · 4:24 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001557376
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $1.67 | Jun 10, 2026 | A | 625,000 | A | Jun 10, 2026 | Jun 10, 2036 | Common Stock | 625,000 | 625,000 | D |
| Stock OptionsF2 | $1.67 | Jun 10, 2026 | A | 625,000 | A | Jun 10, 2026 | Jun 10, 2036 | Common Stock | 625,000 | 625,000 | D |
Explanation of responses
- F1Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan (the "2021 Plan"). The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan.
- F2Represents the grant of stock options to purchase shares of the Issuer's common stock under the 2021 Plan. The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis" during the period commencing on the date they vest and ending ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan. The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock outstanding on a fully diluted basis.